Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation With DOJ

 
• By Brenda Sandburg

Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.

WASHINGTON, DC - MARCH 2018: Headquarters of the U.S. Justice Department. Art Deco aluminum torcheres at doorway. Renamed the Robert F. Kennedy Department of Justice Building in 2001.
Rising Pharmaceuticals is the second company to settle generic price fixing probe with the Department of Justice

More from Generics

More from Biosimilars & Generics